HDAC6 and Sepsis: Recent studies have shown that both class IIa HDACs inhibitors and selective HDAC6 inhibitors attenuate the activation of the ArgBP2/Rho signaling pathway in LPS-activated human lung microvascular endothelial cells (HLMVECs), thereby reducing the level of myosin light chain phosphorylation in VECs and restoring cytoskeletal reorganization, reducing the disruption of the VECs barrier in sepsis-associated ALI, and thereby reducing protein fluid leakage [166].